TSE:IN

InMed Pharmaceuticals Competitors

C$4.19
-0.07 (-1.64 %)
(As of 05/7/2021 04:00 PM ET)
Add
Compare
Today's Range
C$4.13
C$4.27
50-Day Range
C$3.46
C$5.17
52-Week Range
C$3.35
C$13.86
Volume17,035 shs
Average Volume29,552 shs
Market CapitalizationC$33.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

InMed Pharmaceuticals (TSE:IN) Vs. WMD, NINE, ASP, FLWR, RX, and MDP

Should you be buying IN stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to InMed Pharmaceuticals, including WeedMD (WMD), Delta 9 Cannabis (NINE), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), BioSyent (RX), and Medexus Pharmaceuticals (MDP).

WeedMD (CVE:WMD) and InMed Pharmaceuticals (TSE:IN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for WeedMD and InMed Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
WeedMD02002.00
InMed Pharmaceuticals0000N/A

WeedMD presently has a consensus price target of C$0.58, suggesting a potential upside of 97.74%. Given WeedMD's higher probable upside, equities research analysts plainly believe WeedMD is more favorable than InMed Pharmaceuticals.

Valuation and Earnings

This table compares WeedMD and InMed Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WeedMDC$27.21 million2.67C$-21,702,912.00C($0.09)-3.35
InMed PharmaceuticalsN/AN/AN/AC($1.77)-2.36

InMed Pharmaceuticals has lower revenue, but higher earnings than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares WeedMD and InMed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WeedMDN/AN/AN/A
InMed PharmaceuticalsN/AN/AN/A

Summary

WeedMD beats InMed Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

InMed Pharmaceuticals (TSE:IN) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for InMed Pharmaceuticals and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMed Pharmaceuticals0000N/A
Delta 9 Cannabis0000N/A

Valuation & Earnings

This table compares InMed Pharmaceuticals and Delta 9 Cannabis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMed PharmaceuticalsN/AN/AN/AC($1.77)-2.36
Delta 9 CannabisC$12.87 million6.94C$4.69 millionC$0.0519.07

Delta 9 Cannabis has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InMed Pharmaceuticals and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMed PharmaceuticalsN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Summary

Delta 9 Cannabis beats InMed Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

InMed Pharmaceuticals (TSE:IN) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Profitability

This table compares InMed Pharmaceuticals and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMed PharmaceuticalsN/AN/AN/A
Acerus PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares InMed Pharmaceuticals and Acerus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMed PharmaceuticalsN/AN/AN/AC($1.77)-2.36
Acerus PharmaceuticalsC$1.09 million70.86C$-55,353,168.00C($0.04)-1.39

InMed Pharmaceuticals has higher earnings, but lower revenue than Acerus Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for InMed Pharmaceuticals and Acerus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMed Pharmaceuticals0000N/A
Acerus Pharmaceuticals0000N/A

Summary

Acerus Pharmaceuticals beats InMed Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

The Flowr (CVE:FLWR) and InMed Pharmaceuticals (TSE:IN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares The Flowr and InMed Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrC$7.51 million12.04C$-343,678,650.00C($0.95)-0.26
InMed PharmaceuticalsN/AN/AN/AC($1.77)-2.36

InMed Pharmaceuticals has lower revenue, but higher earnings than The Flowr. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares The Flowr and InMed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
InMed PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for The Flowr and InMed Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr0000N/A
InMed Pharmaceuticals0000N/A

The Flowr currently has a consensus price target of C$0.88, suggesting a potential upside of 253.33%. Given The Flowr's higher possible upside, equities research analysts clearly believe The Flowr is more favorable than InMed Pharmaceuticals.

Summary

The Flowr beats InMed Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

BioSyent (CVE:RX) and InMed Pharmaceuticals (TSE:IN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares BioSyent and InMed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSyentN/AN/AN/A
InMed PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares BioSyent and InMed Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSyentC$22.33 million4.38C$3.68 millionC$0.2926.55
InMed PharmaceuticalsN/AN/AN/AC($1.77)-2.36

BioSyent has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for BioSyent and InMed Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSyent02002.00
InMed Pharmaceuticals0000N/A

BioSyent presently has a consensus price target of C$7.00, indicating a potential downside of 9.09%. Given BioSyent's higher probable upside, equities analysts plainly believe BioSyent is more favorable than InMed Pharmaceuticals.

Summary

BioSyent beats InMed Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

InMed Pharmaceuticals (TSE:IN) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for InMed Pharmaceuticals and Medexus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMed Pharmaceuticals0000N/A
Medexus Pharmaceuticals00203.00

Valuation & Earnings

This table compares InMed Pharmaceuticals and Medexus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMed PharmaceuticalsN/AN/AN/AC($1.77)-2.36
Medexus PharmaceuticalsC$108.29 million1.26C$-34,573,801.00C($1.81)-3.94

InMed Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InMed Pharmaceuticals and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMed PharmaceuticalsN/AN/AN/A
Medexus PharmaceuticalsN/AN/AN/A


InMed Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WMD
WeedMD
1.3$0.30-1.7%C$95.35 millionC$27.21 million-3.35
NINE
Delta 9 Cannabis
1.1$1.03-2.9%C$89.36 millionC$12.87 million19.07Gap Up
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05-0.0%C$76.88 millionC$1.09 million-1.39News Coverage
Gap Up
FLWR
The Flowr
1.0$0.25-4.0%C$70.01 millionC$7.51 million-0.26
RX
BioSyent
0.8$7.70-1.3%C$64.81 millionC$22.33 million26.55Gap Down
MDP
Medexus Pharmaceuticals
0.6$7.14-1.5%C$38.66 millionC$108.29 million-3.94
VIR
Viridium Pacific Group
0.7$0.38-5.3%C$37.54 millionC$1.09 million-2.97Gap Up
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29-7.0%C$36.73 millionN/A-2.61News Coverage
Gap Down
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.31-3.8%C$35.34 millionC$21.61 million6.42Upcoming Earnings
Gap Down
NDVA
Indiva
1.3$0.45-7.8%C$27.54 millionC$7.92 million-3.52News Coverage
Gap Up
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.10-0.0%C$21.51 millionC$8.50 million-0.27
EVE
Eve & Co Incorporated
1.0$0.28-5.5%C$21.32 millionC$2.84 million-0.86Upcoming Earnings
Gap Down
SUGR
SugarBud Craft Growers
0.7$0.05-10.0%C$11.81 millionC$66,906.00-0.03Gap Up
NU
NeutriSci International
0.5$0.16-6.3%C$8.65 millionC$74,572.00-11.43Gap Up
AQS
Aequus Pharmaceuticals
0.9$0.16-0.0%C$6.03 millionC$2.59 million-14.55
LBL
Lattice Biologics
0.5$0.04-12.5%C$4.67 millionC$2.24 million-2.22Gap Down
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5$30.80-3.4%C$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.